期刊文献+

葡激酶蛋白质工程研究进展 被引量:1

Research development of protein engineering of staphylokinase
下载PDF
导出
摘要 近年来,葡激酶的蛋白质工程研究取得了快速进展,主要介绍了葡激酶分子的高级结构、纤溶酶原激活机制、免疫原性的研究进展以及新型葡激酶突变体的分子设计和改造的研究概况。 In recent years, the staphylokinase protein engineering develops very rapidly. The recent research development of staphylokinase, such as the three-dimensional structure, the mechanisms of plasminogen activation, and immunogenicity, are introduced. The molecular design and clinical prospect of recombinant staphylokinase variants with reduced antigenicity and unaltered potency is also discussed.
出处 《河北工业科技》 CAS 2007年第5期309-313,共5页 Hebei Journal of Industrial Science and Technology
关键词 葡激酶 蛋白质工程 纤溶酶原 staphylokinase protein engineering plasminogen
  • 相关文献

参考文献4

二级参考文献38

  • 1周文孝,袁庆辉.聚乙二醇在生化药物化学修饰中的应用[J].中国药学杂志,1997,32(3):132-134. 被引量:10
  • 2汤其群,张小璇,于敏,宋后燕.重组葡激酶(r-Sak)的分离、纯化和结晶[J].药物生物技术,1997,4(1):1-4. 被引量:15
  • 3Symon Z,Peyser A,Tzemach D,et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer, 1999,86 ( 1 ) :72-78.
  • 4Heathcote E J, Shiffman ML, Cooksley WG, et al.Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med, 2000, 343 (23):1673-1680.
  • 5Hershfield MS. PEG-ADA replacement therapy for adenosine deaminase deficiency., an update after 8.5 years. Clin Immunol Immunopathol, 1995, 76 (3 Pt2) :S228-S232.
  • 6Holle LM. Pegaspargase :an alternative? Ann Pharmacother, 1997,31 (5) :616-624.
  • 7Davis-Daneshfar A,Boni R,von Wussow P,et al. Adjuvant immunotherapy in malignant melanoma :impact of antibody formation against interferon-alpha on immunoparameters in vivo. J Immunother, 1997,20 (3)208-213.
  • 8Bailon P,Palleroni A,Schaffer CA,et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem, 2001,12(2) : 195-202.
  • 9Zeuzem S, Feinman SV, Rasenack J,et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med,2000,343(23) : 1666-1672.
  • 10Gupta SK,Pittenger AL,Swan SK,et al. Single-dose pharmacokinetics and safety of peglated interferon-a 2b in patients with chronic renal dysfunction. J Clin Pharmacol, 2002,42(10) : 1109-1115.

共引文献42

同被引文献6

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部